ArticleJournal of pharmaceutical health care and sciences2026
Akathisia induced by concurrent use of mirogabalin and sulfamethoxazole-trimethoprim: a case report.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMirogabalin and trimethoprim-sulfamethoxazole (TMP/SMX) are frequently used as supportive purpose during and/or after chemotherapy. Mirogabalin is used to treat neuropathic pain, whereas TMP/SMX is used to prevent pneumocystis pneumonia (PCP) in patients who are immunocompromised. The interaction between mirogabalin and TMP/SMX has not been reported. Here, we report a case of akathisia that developed after concurrent administration of mirogabalin and TMP/SMX. CASE PRESENTATION: We report the case of a 69-year-old male patient who experienced akathisia twice. The patient was diagnosed with diffuse large B-cell lymphoma and treated with the polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) regimen. On the fifth day of treatment, TMP/SMX at a dosage of 80 mg/400 mg once daily was initiated to prevent PCP. On day 20 of treatment, mirogabalin treatment was initiated for neuropathic pain probably due to polatuzumab vedotin. Akathisia first manifested on the day following the initiation of mirogabalin treatment, occurring 30 min after the administration of TMP/SMX. The patient experienced pruritus and dyspnea. Discontinuation of TMP/SMX resulted in the amelioration of symptoms. Akathisia occurred a second time, when TMP/SMX was resumed, resulting in itching of the upper body, symptoms of restlessness, and an inability to remain still. Based on these symptoms, the patient was diagnosed with akathisia. Following discontinuation of both TMP/SMX and mirogabalin, the symptoms improved. These episodes suggested the possibility that the concurrent use of mirogabalin and TMP/SMX caused akathisia. Blood concentration measurements obtained at symptom onset did not reveal a significant increase in mirogabalin levels, suggesting that the adverse event was unlikely to be explained solely by an increase in mirogabalin concentration.
conclusionsConcurrent use of mirogabalin and TMP/SMX may have been associated with the development of akathisia in the present case. Based on the potential for similar interactions, caution should be exercised when administering this drug to patients undergoing chemotherapy. To the best of our knowledge, this is the first case report describing akathisia associated with the concomitant use of mirogabalin and TMP/SMX, highlighting the need for careful monitoring of patients receiving both drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.